IFRX
InflaRx N.V.
There isn't enough reported data to score IFRX yet.
IFRX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Unavailable | |
| Unavailable |
IFRX's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
IFRX PE Valuation
IFRX has no meaningful PE right now: it lost money over the past year.
IFRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect IFRX's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
IFRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.54 | +$0.27 |
| Q1 2026 | -$0.68 | +$0.16 |
| Q4 2025 | -$0.73 | +$0.14 |
| Q3 2025 | -$0.67 | +$0.40 |
| Q2 2025 | -$0.81 | +$0.07 |
| Q1 2025 | -$0.84 | -$0.07 |
| Q4 2024 | -$0.87 | +$0.02 |
| Q3 2024 | -$1.07 | -$0.25 |
IFRX is still losing money, but far less than before: $0.54 per share over the past year, against $2.28 at its worst in late 2019.
IFRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2025 | $26.5K | -81% |
| Q2 2025 | $43.8K | +520% |
| Q3 2024 | $137.6K | +104% |
IFRX's revenue has slid since its 2024 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2025 | -39769% | -27364 points |
| Q2 2025 | -32525% | +209675 points |
| Q3 2024 | -12405% | +5934 points |
| Q2 2024 | -242200% | N/A |
| Q1 2024 | -34655% | N/A |
| Q4 2023 | -582075% | N/A |
| Q3 2023 | -18339% | N/A |
IFRX's operating margin was −39769% last quarter, down 5114 points from the same quarter a year ago.
IFRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2.9M | +$5.5M |
| Q1 2026 | -$8.4M | +$7.2M |
| Q4 2025 | -$5.2M | +$8M |
| Q3 2025 | -$10.1M | +$592.1K |
| Q2 2025 | -$8.4M | +$5.1M |
| Q1 2025 | -$15.6M | +$953.5K |
| Q4 2024 | -$13.2M | -$1.1M |
| Q3 2024 | -$10.7M | -$4.9M |
IFRX has burned cash in almost every quarter: −$27M over the past year, against −$48M the year before.
IFRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +63% | +45.4M shares |
| 1 year | +74% | +49.9M shares |
| 3 years | +106% | +60.7M shares |
| 5 years | +166% | +73.5M shares |
| Available history | +353% | +91.7M shares |
IFRX has 118M diluted shares, up 74% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
IFRX hasn't bought back shares in the past year.
IFRX Net Leverage
IFRX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
IFRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.3 | Neutral |
| Stochastic | 15.9 | Oversold |
IFRX's weekly RSI is 39 (neutral) and its Stochastic is 16 (oversold).
IFRX PE vs Healthcare Sector
IFRX has no meaningful PE right now: it lost money over the past year.
IFRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.54 | 19% below |
| 20 week MA | $1.82 | 32% below |
| 50 week MA | $1.55 | 20% below |
| 100 week MA | $1.48 | 16% below |
| 200 week MA | $1.91 | 35% below |
IFRX is in a downtrend: it's below all five of its weekly moving averages, and 35% below its 200-week average.
IFRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.33 | $5.05 | +17% |
| 2021 | $5.05 | $4.65 | -7.9% |
| 2022 | $4.65 | $3.25 | -30% |
| 2023 | $3.25 | $1.63 | -50% |
| 2024 | $1.63 | $2.59 | +59% |
| 2025 | $2.59 | $1.10 | -58% |
| 2026 YTD | $1.10 | $1.24 | +13% |
IFRX has finished lower in four of the last six years. It's up 13% so far in 2026.